Home

What's next for Antisense Therapeutics?

PUBLISHED

2020-11-19

Content

[embed]https://player.vimeo.com/video/481053509[/embed]

Mark Diamond, CEO and Managing Director of Australian biotech company Antisense Therapeutics (ASX: ANP), discusses the firm’s latest goings-on with Share Cafe’s Tim McGowen.

Key points in the video:


  • details of ANP’s recent $A7.6m capital raising and how it plans to use the money

  • what the company’s share registry looks like post this placement

  • 2021 and what it holds for Antisense

  • the company’s plans with regard to overseas listings